Tompkins Wake advises on $21.4b global biopharma transaction

Friday 8 March, 2019

Tompkins Wake is pleased to have advised Fortune 500 and NYSE listed science and technology innovator Danaher, on a significant transaction to expand their global reach. Danaher operates more than 20 operating companies with a global team of 59,000 associates.

The Tompkins Wake team, led by corporate partner Mark Renner advised global science and technology innovator Danaher on the New Zealand aspects of its acquisition of the Biopharma business of GE Life Sciences ("GE Biopharma") for a cash purchase price of approximately $21.4 billion. The deal involved coordinating as part of a global acquisition process as well as New Zealand Overseas Investment Office regulatory compliance for foreign ownership.